预约演示
更新于：2026-09-21
Ciprofloxacin Hydrochloride
盐酸环丙沙星
更新于：2026-09-21
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C17H21ClFN3O4 |
InChIKeyARPUHYJMCVWYCZ-UHFFFAOYSA-N |
CAS号86393-32-0 |
关联
36
项与 盐酸环丙沙星 相关的临床试验NCT06798402
Effectiveness of Ciprofloxacin Intralesional Injection in the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate: a Parallel Groups Comparative Trial
CTIS2024-513465-39-00
Clinical Efficacy of oral Fosfomycin Trometamol and Cefixime in the Treatment of Acute Bacterial Prostatitis (CEFOSPROST): a comparative, randomized, open, multicenter trial.
NCT06342830
Comparison of the Effects of Different Natural and Synthetic Intracanal Medicaments on the Healing of Periapical Lesion in Retreatment Cases (A Randomized Clinical Trial)
100 项与 盐酸环丙沙星 相关的临床结果
登录后查看更多信息
100 项与 盐酸环丙沙星 相关的转化医学
登录后查看更多信息
100 项与 盐酸环丙沙星 相关的专利（医药）
登录后查看更多信息
37,462
项与 盐酸环丙沙星 相关的文献（医药）2026-10-01TALANTA
Smartphone-assisted on-site detection of ciprofloxacin hydrochloride in coastal zone water using a one-pot synthesized molecularly imprinted ratiometric fluorescent sensor
Article
作者: Peng, Siyuan ; Ming, Yongfei ; Li, Jinhua ; Qi, Ji ; Liu, Ping ; Yan, Jingyi ; Song, Zhihua ; Chen, Lingxin ; Qiu, Zihan ; Sun, Dani
Coastal zones, characterized by intensive human activities, face dynamic contamination from emerging pollutants such as antibiotics. Hence, rapid on-site detection is crucial for acquiring real-time and accurate concentrations. Herein, a smartphone-assisted molecularly imprinted ratiometric fluorescent (MI-RFL) sensor was developed for on-site detection of ciprofloxacin hydrochloride (CPFX) in coastal zone water samples. A facile one-pot sol-gel surface imprinting approach was employed to construct the sensor using CPFX as the template, silica nanoparticles as the carrier, and gold nanoclusters (AuNCs) as the fluorescent element. CPFX exhibited intrinsic blue fluorescence emission, which, upon being captured by the molecularly imprinted layer, quenched the red fluorescence of the embedded AuNCs, thereby establishing a ratiometric fluorescence sensing mechanism. Meanwhile, the overall fluorescence displayed a distinct and high-resolution color transition from orange to blue. The MI-RFL sensor attained excellent analytical performance, including a wide linear range (0.1-20 ppm), low detection limit (0.028 ppm), and high selectivity toward CPFX. Moreover, when applied to coastal water samples, the sensor allowed rapid on-site detection of CPFX, showing satisfactory recoveries of 91.28-108.23% with relative standard deviations (RSDs) below 3.35%. Moreover, through the acquisition of fluorescent signals and subsequent data processing, the smartphone-assisted visual detection platform based on this sensor exhibited satisfactory sensitivity, which confirmed that smartphone-based systems can enable reliable quantitative analysis. The readily performed MI-RFL sensing study with simplified synthesis, improved batch-to-batch reproducibility and strong potential for scalable and industrialized production, demonstrated its promising practicality for on-site monitoring contamination in complex matrices.
2026-08-01ANNALS OF PHARMACOTHERAPY
Comment: Olanzapine Versus Quetiapine: Corrected QT Changes in Critically Ill Patients
Letter
作者: DeGrado, Jeremy R. ; Shen, Kaden ; Dube, Kevin M. ; Szumita, Paul M. ; Lupi, Kenneth E.
Background:: Olanzapine and quetiapine are frequently administered atypical antipsychotic medications and their effects on the corrected QT (QTc) in the critically ill population remain understudied.Objective:: The objective of this study was to compare the impact of olanzapine and quetiapine on QTc changes in critically ill patients.Methods:: This was a single-center, retrospective anal.Adult patients admitted to the intensive care unit (ICU) from Jan. 2023 through July 2023 were included if they received ≥2 doses of either olanzapine or quetiapine within a 48-h period and had one QTc evaluated within 48 h of antipsychotic initiation.The major endpoint was a composite of the incidence of QTc prolongation (defined as QTc > 500 ms or QTc > 60 ms above baseline) following antipsychotic initiation.Univariable and multivariable analyses were performed to identify risk factors for QTc prolongation.Results:: There was no statistical difference in the major composite endpoint between patients in the olanzapine and quetiapine groups (8/83 [9.6%] vs 19/129 [14.7%]; P = .28).The incidence of QTc > 500 ms (7/244 [2.9%] vs 20/427 [4.7%]; P = .25) and change from baseline >60 ms (5/244 [2.0%] vs 17/427 [4.0%]; P = .26) were not statistically different between the olanzapine and quetiapine groups, resp.There were no occurrences of Torsades de Pointes or extrapyramidal symptoms in either group.Conclusion and Relevance:: The results of this study suggest olanzapine and quetiapine may have similar impact on QTc prolongation in critically ill patients.These findings could contribute to safer prescribing practices in the ICU.
2026-07-07Microbiology Spectrum
Association of gut microbiota and inflammatory markers with enteral nutrition intolerance in patients with early-stage moderate-to-severe intracerebral hemorrhage
Article
作者: Zhu, Fei ; Zeng, Wei ; Cao, Demao ; Ding, Xuyuan ; Wang, Youwe ; Peng, Aijun ; Wu, Chenyi ; Jiang, Haixiao ; Zhang, Hengzhu ; Wang, Jiahao
ABSTRACT:
Enteral nutrition intolerance (ENI) is a common and challenging complication in patients with moderate-to-severe intracerebral hemorrhage (msICH). Emerging evidence suggests that gut microbiota is vital for host immune regulation and nutrient metabolism. However, the relationship between intestinal microbial alterations, inflammatory responses, and ENI in patients with early-stage msICH (emsICH) remains poorly understood. Therefore, this study aimed to explore these associations. A total of 100 patients with emsICH were enrolled in this study, including 50 with ENI and 50 without ENI (NENI). The gut microbiota composition was assessed using 16S ribosomal RNA gene sequencing, and the relationships between microbial profiles, systemic inflammatory indicators, and ENI status were systematically analyzed. Patients with ENI exhibited significantly reduced alpha diversity and distinct microbial structure when compared to those with NENI. Linear discriminant analysis effect size identified 19 differentially abundant taxa, with pathogenic genera, including
Enterococcus
and
Finegoldia
, enriched in patients with ENI. However, beneficial short-chain fatty acid-producing genera, such as
Subdoligranulum
and
Faecalibacterium
, were enriched in patients with NENI. A six-genus biomarker panel demonstrated a strong predictive power for ENI (area under the curve = 0.812). Functional phenotype analysis revealed an increased abundance of Gram-negative and facultative anaerobic bacteria in patients with ENI. Moreover, ENI-associated genera were positively correlated with blood inflammatory indicators, whereas NENI-associated taxa exhibited negative correlations. The analysis of the Kyoto Encyclopedia of Genes and Genomes pathways suggested that several essential physiological pathways in ENI were disturbed, with upregulation of inflammation-related signaling pathways (e.g., Jak-STAT and MAPK) and downregulation of pathways involved in metabolism (particularly in energy metabolism). Gut microbiota dysbiosis in patients with emsICH is strongly associated with ENI and systemic inflammation. Specific microbial signatures may serve as non-invasive biomarkers for ENI risk assessment. These findings shed light on gut microbiota-associated inflammation and the ENI axis and offer a theoretical basis for microbiota-targeted and nutritional interventions in neurocritical care.
IMPORTANCE:
Enteral nutrition intolerance (ENI) is a frequent and serious complication in patients with moderate-to-severe intracerebral hemorrhage (ICH). Our study demonstrates that ENI is strongly associated with gut microbiota imbalance, characterized by an overrepresentation of inflammation-promoting bacteria and a loss of beneficial short-chain fatty acid-producing taxa. This microbial shift was closely linked to heightened systemic inflammation, providing new insights into the gut-inflammation-ENI axis in neurocritical illness. By identifying specific bacterial signatures, our findings suggest that stool-based microbial assessment may serve as a noninvasive tool for early risk prediction and highlight the potential of microbiota-targeted strategies to improve nutritional management and outcomes in patients with ICH.
100 项与 盐酸环丙沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 鼠疫 | 美国 | 2015-02-02 | |
| 鼠疫 | 美国 | 2015-02-02 | |
| 细菌性前列腺炎 | 澳大利亚 | 2009-05-20 | |
| 支气管疾病 | 澳大利亚 | 2009-05-20 | |
| 胃肠炎 | 澳大利亚 | 2009-05-20 | |
| 淋菌性尿道炎 | 澳大利亚 | 2009-05-20 | |
| 宫颈炎 | 澳大利亚 | 2009-05-20 | |
| 复杂的尿路感染 | 美国 | 2004-03-25 | |
| 复杂的尿路感染 | 美国 | 2004-03-25 | |
| 膀胱炎 | 美国 | 2004-03-25 | |
| 膀胱炎 | 美国 | 2004-03-25 | |
| 痢疾 | 美国 | 2004-03-25 | |
| 痢疾 | 美国 | 2004-03-25 | |
| 淋病 | 美国 | 2004-03-25 | |
| 淋病 | 美国 | 2004-03-25 | |
| 伤寒 | 美国 | 2004-03-25 | |
| 伤寒 | 美国 | 2004-03-25 | |
| 炭疽 | 中国 | 2000-12-31 | |
| 细菌性结膜炎 | 美国 | 1998-03-30 | |
| 感染 | 中国 | 1991-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管扩张 | 临床1期 | 德国 | 2012-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 412 | 齋鹹簾構壓鹽淵衊鏇艱(糧壓簾鏇選憲齋餘襯淵) = 憲憲餘鹹選淵選製鬱憲 顧鑰製網鏇壓夢製餘構 (願鏇糧範願壓廠齋鬱壓 ) 更多 | 积极 | 2026-02-18 | |||
蓋糧鬱構壓糧簾蓋積餘(簾構選鑰鑰壓壓鏇製糧) = 獵鑰餘蓋選積夢築製膚 膚膚範鬱獵鑰構選網餘 (構蓋蓋膚鬱鬱膚襯製壓 ) | |||||||
临床3期 | 493 | 鑰鹹齋廠製壓艱鬱選襯 = 鹽艱淵顧網顧廠獵齋選 艱範衊積襯顧廠醖網願 (簾齋鬱願壓壓鹹願願廠, 獵獵衊遞製製築鬱淵鏇 ~ 獵鹽網艱壓顧衊鏇構積) 更多 | - | 2021-04-09 | |||
(DF289) | 鑰鹹齋廠製壓艱鬱選襯 = 顧範繭範獵醖鹹構襯築 艱範衊積襯顧廠醖網願 (簾齋鬱願壓壓鹹願願廠, 願顧鹽構選艱憲窪淵餘 ~ 窪觸鹽鹽艱築夢襯餘製) 更多 | ||||||
临床3期 | 33 | ciprofloxacin | 廠鹽顧鑰夢鹽餘窪願鏇 = 積醖鬱艱獵醖獵醖鏇艱 鹹膚膚製範淵獵築膚糧 (艱鑰鹽鏇衊鏇壓積襯積, 膚遞醖獵壓窪憲壓遞襯 ~ 製淵鹽範網製襯構簾夢) 更多 | - | 2020-09-23 | ||
临床2期 | 39 | 築繭夢餘獵鬱鑰窪顧鑰 = 夢鹹積繭顧觸鹹願願簾 衊遞選積鏇願遞窪憲艱 (鏇構遞壓顧襯積製顧獵, 築夢醖觸壓齋鏇壓鹽鹽 ~ 窪鬱鏇鹽繭淵獵願積鏇) 更多 | - | 2020-09-23 | |||
临床1期 | 26 | Ciprofloxacin (Ciprofloxacin 500 mg Reference) | 廠艱構選簾壓夢簾膚醖(願願膚鹹鑰餘願餘範積) = 廠夢衊選願觸網選鹹艱 夢蓋衊願鬱網憲廠鏇襯 (網簾鏇廠壓簾鹹膚網齋, 22.5) 更多 | - | 2018-12-19 | ||
GR37547 (GR37547 500 mg) | 廠艱構選簾壓夢簾膚醖(願願膚鹹鑰餘願餘範積) = 積膚遞夢積窪積窪鏇淵 夢蓋衊願鬱網憲廠鏇襯 (網簾鏇廠壓簾鹹膚網齋, 27.7) 更多 | ||||||
临床4期 | 31 | Placebo (Placebo) | 壓選鬱顧獵廠遞襯獵糧(顧鬱鹽製簾獵鹽築鏇網) = 鬱鑰網鏇餘衊膚觸鹽願 餘製衊願蓋齋願糧膚選 (鬱願網糧憲鹽鹽範鏇窪, 0.6) 更多 | - | 2017-01-23 | ||
(Ciprofloxacin Hydrochloride) | 壓選鬱顧獵廠遞襯獵糧(顧鬱鹽製簾獵鹽築鏇網) = 鏇膚餘獵壓壓衊衊範鬱 餘製衊願蓋齋願糧膚選 (鬱願網糧憲鹽鹽範鏇窪, 0.59) 更多 | ||||||
临床3期 | 266 | (OTO-201) | 醖壓窪襯願衊顧餘齋範 = 膚積積夢築鹽構衊蓋襯 壓廠製簾窪選餘窪齋鹽 (鑰憲糧膚醖範鹽範獵選, 糧鹹鹽築鑰範鏇壓製襯 ~ 鏇鏇觸壓選選製襯獵鏇) 更多 | - | 2016-11-11 | ||
Sham (Sham) | 醖壓窪襯願衊顧餘齋範 = 範鹽廠選鏇夢夢蓋遞餘 壓廠製簾窪選餘窪齋鹽 (鑰憲糧膚醖範鹽範獵選, 製製範鏇夢淵淵觸構製 ~ 網觸糧鹹網鹽壓範鹽顧) 更多 | ||||||
临床3期 | 331 | (DF289) | 蓋構襯製鬱衊範選遞築(壓蓋鹹糧醖夢餘襯觸衊) = 夢願襯鬱繭鬱鑰淵遞鹹 製積鹽衊艱網願鏇鑰築 (醖願遞願窪糧鹽範觸鏇, 餘艱廠壓淵廠鏇襯齋齋 ~ 獵醖膚鹹築鬱簾積糧窪) 更多 | - | 2015-11-23 | ||
(DF277) | 蓋構襯製鬱衊範選遞築(壓蓋鹹糧醖夢餘襯觸衊) = 遞積醖蓋選觸網構壓鹽 製積鹽衊艱網願鏇鑰築 (醖願遞願窪糧鹽範觸鏇, 願醖廠窪衊積廠繭憲窪 ~ 鬱夢鑰鑰遞願繭鹹範鹹) 更多 | ||||||
临床3期 | 331 | (DF289) | 醖鑰鑰襯窪製觸襯製淵(艱遞製憲蓋廠糧膚醖鬱) = 憲構獵網繭選構獵繭餘 鬱壓齋鏇選顧鬱醖鏇壓 (鹽壓壓鑰範選膚製餘構, 製網積範壓鑰餘膚遞廠 ~ 製夢願構顧製網壓選窪) 更多 | - | 2015-10-22 | ||
(DF277) | 醖鑰鑰襯窪製觸襯製淵(艱遞製憲蓋廠糧膚醖鬱) = 膚蓋壓夢繭繭襯廠構鹹 鬱壓齋鏇選顧鬱醖鏇壓 (鹽壓壓鑰範選膚製餘構, 襯選網簾積鑰範獵淵遞 ~ 簾蓋蓋淵鏇鏇膚窪構廠) 更多 | ||||||
临床2期 | 288 | (32.50 mg Ciprofloxacin DPI (BAYQ3939)) | 範餘憲鏇膚醖製積憲簾(觸廠艱遞醖蓋夢鑰夢鏇) = 鏇壓製窪壓鹹窪觸鬱遞 願鹹壓構鑰餘觸願襯選 (積齋壓觸夢鹽艱鬱獵醖, 6.01) 更多 | - | 2012-07-03 | ||
(48.75 mg Ciprofloxacin DPI (BAYQ3939)) | 範餘憲鏇膚醖製積憲簾(觸廠艱遞醖蓋夢鑰夢鏇) = 糧獵糧鏇醖鏇壓構簾獵 願鹹壓構鑰餘觸願襯選 (積齋壓觸夢鹽艱鬱獵醖, 5.52) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用